<DOC>
	<DOCNO>NCT01637025</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Traumastem help stop bleeding participant undergo open cardiac , intra-abdominal ( include retroperitoneal ) pelvic surgery compare Surgicel® Original ( Surgicel ; country market Tabotamp® )</brief_summary>
	<brief_title>Oxidized Cellulose hEmostAsis evaluatioN</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Cellulose , Oxidized</mesh_term>
	<criteria>INCLUSION CRITERIA AT SCREENING : 1 . Participants and/or legal representative has/have provide sign informed consent . An assent form sign Participants le 18 year age , possible ; 2 . Participants undergo plan ( nonemergency ) open cardiac , intraabdominal ( include retroperitoneal ) pelvic surgery ; 3 . Participants childbearing potential present negative serum pregnancy test , agree employ adequate birth control measure duration study . Acceptable contraception method restrict abstinence , barrier contraceptive , intrauterine contraceptive device license hormonal product ; 4 . Participants willing able comply requirement clinical investigation plan ( CIP ) . INCLUSION CRITERIA INTRAOPERATIVE : 5 . Soft tissue , vascular/anastomotic parenchymal bleed present primary surgical hemostasis achieve . The TBS define intraoperative bleeding conventional method achieve hemostasis ineffective ( base type tissue ) impractical ( base location ) treatment topical hemostatic adjunct Traumastem deem appropriate use . EXCLUSION CRITERIA : 1 . Emergency surgery ; 2 . Transplantation surgery ; 3 . Minimally invasive surgery ; 4 . Neurological ophthalmological surgery ; 5 . Major arterial bleed target bleed site ( TBS ) ; 6 . Major intraoperative complication require resuscitation deviation plan surgical procedure ; 7 . Severe local inflammation operate field ; 8 . Any prior radiation therapy operate field ; 9 . Known severe congenital acquire immunodeficiency ( eg , human immunodeficiency virus [ HIV ] infection longterm [ &gt; 3 month ] treatment immunosuppressive drug ) ; 10 . Known hypersensitivity component investigational device ; 11 . Participant pregnant lactating time enrollment becomes pregnant prior plan surgery . If participant becomes pregnant 30 day follow treatment exposure , attempt make follow completion pregnancy . The investigator record narrative description course pregnancy outcome ; 12 . Participant clinically significant medical , psychiatric , cognitive illness , drug/alcohol abuse , opinion investigator , would affect participant 's safety compliance ; 13 . Participant participate another clinical study involve investigational device/drug within 30 day prior enrollment schedule participate another clinical study involve investigational device/drug course study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>